Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study.
ATTR-CA
Frailty
KCCQ
Quality of life
Social environment
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
10 Apr 2024
10 Apr 2024
Historique:
received:
12
03
2024
accepted:
27
03
2024
medline:
10
4
2024
pubmed:
10
4
2024
entrez:
10
4
2024
Statut:
epublish
Résumé
Whether, and to what extent, frailty and other geriatric domains are linked to health status in patients with transthyretin cardiac amyloidosis (ATTR-CA) is unknown. To determine the association of frailty with health status [defined by the Kansas City Cardiomyopathy Questionnaire (KCCQ)] in patients with ATTR-CA. Consecutive ATTR-CA patients undergoing cardiovascular assessment at a tertiary care clinic from September 2021 to September 2023 were invited to participate. KCCQ, frailty and social environment were recorded. Frailty was assessed using the modified Frailty Index (mFI), mapping 11 variables from the Canadian Study of Health and Aging (frailty ≥0.36). Of 168 screened ATTR-CA patients, 138 [83% men, median age of 79 (75-84) years] were enrolled in the study. Median KCCQ was 66 (50-75). wtATTR-CA was the most prevalent form (N = 113, 81.9%). The most frequent cardiac variant was Ile68Leu (17/25 individuals with vATTR-CA). Twenty (14.5%) patients were considered frail, and prevalence of overt disability was 6.5%. At multivariable linear regression analysis, factors associated with worsening KCCQ were age at evaluation, the mFI, NYHA Class, and NAC Score. Gender, ATTR-CA type, phenotype, and LVEF were not associated with health status. In older patients diagnosed with ATTR-CA, frailty, symptoms, and disease severity were associated with KCCQ. Functional status is a determinant of quality of life and health status in older individuals with a main diagnosis of ATTR-CA. Future research may provide more in-depth knowledge on the association of frailty in patients with ATTR-CA with respect to quality of life and prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Whether, and to what extent, frailty and other geriatric domains are linked to health status in patients with transthyretin cardiac amyloidosis (ATTR-CA) is unknown.
AIMS
OBJECTIVE
To determine the association of frailty with health status [defined by the Kansas City Cardiomyopathy Questionnaire (KCCQ)] in patients with ATTR-CA.
METHODS
METHODS
Consecutive ATTR-CA patients undergoing cardiovascular assessment at a tertiary care clinic from September 2021 to September 2023 were invited to participate. KCCQ, frailty and social environment were recorded. Frailty was assessed using the modified Frailty Index (mFI), mapping 11 variables from the Canadian Study of Health and Aging (frailty ≥0.36).
RESULTS
RESULTS
Of 168 screened ATTR-CA patients, 138 [83% men, median age of 79 (75-84) years] were enrolled in the study. Median KCCQ was 66 (50-75). wtATTR-CA was the most prevalent form (N = 113, 81.9%). The most frequent cardiac variant was Ile68Leu (17/25 individuals with vATTR-CA). Twenty (14.5%) patients were considered frail, and prevalence of overt disability was 6.5%. At multivariable linear regression analysis, factors associated with worsening KCCQ were age at evaluation, the mFI, NYHA Class, and NAC Score. Gender, ATTR-CA type, phenotype, and LVEF were not associated with health status.
DISCUSSION
CONCLUSIONS
In older patients diagnosed with ATTR-CA, frailty, symptoms, and disease severity were associated with KCCQ.
CONCLUSIONS
CONCLUSIONS
Functional status is a determinant of quality of life and health status in older individuals with a main diagnosis of ATTR-CA. Future research may provide more in-depth knowledge on the association of frailty in patients with ATTR-CA with respect to quality of life and prognosis.
Identifiants
pubmed: 38598143
doi: 10.1007/s40520-024-02750-6
pii: 10.1007/s40520-024-02750-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
89Informations de copyright
© 2024. The Author(s).
Références
Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42:1554–1568. https://doi.org/10.1093/EURHEARTJ/EHAB072
doi: 10.1093/EURHEARTJ/EHAB072
pubmed: 33825853
pmcid: 8060056
Ioannou A, Patel RK, Razvi Y et al (2022) Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years. Circulation 146:1657–1670. https://doi.org/10.1161/CIRCULATIONAHA.122.060852
doi: 10.1161/CIRCULATIONAHA.122.060852
pubmed: 36325894
pmcid: 9698091
Fumagalli C, Zampieri M, Perfetto F et al (2021) Early diagnosis and outcome in patients with wild-type transthyretin cardiac amyloidosis. Mayo Clin Proc 96:2185–2191. https://doi.org/10.1016/J.MAYOCP.2021.04.021
doi: 10.1016/J.MAYOCP.2021.04.021
pubmed: 34353472
Elliott P, Drachman BM, Gottlieb SS et al (2022) Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ Heart Fail 15:e008193 https://doi.org/10.1161/CIRCHEARTFAILURE.120.008193
doi: 10.1161/CIRCHEARTFAILURE.120.008193
pubmed: 34923848
Ponti L, Smorti M, Pozza F et al (2023) Anxious/depressive symptoms alter the subjective perception of heart failure severity in transthyretin cardiac amyloidosis. Am J Cardiol 192:1–6. https://doi.org/10.1016/j.amjcard.2023.01.007
doi: 10.1016/j.amjcard.2023.01.007
pubmed: 36689900
Smorti M, Ponti L, Soffio F et al (2023) Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis. Front Psychol 13:1066224. https://doi.org/10.3389/fpsyg.2022.1066224
doi: 10.3389/fpsyg.2022.1066224
pubmed: 36743650
pmcid: 9889831
Cappelli F, Del Franco A, Vergaro G et al (2023) Prevalence of transthyretin-related amyloidosis in Tuscany: data from the regional population-based registry. Int J Cardiol 382:87–90. https://doi.org/10.1016/j.ijcard.2023.03.063
doi: 10.1016/j.ijcard.2023.03.063
pubmed: 37004943
Hoogendijk EO, Afilalo J, Ensrud KE et al (2019) Frailty: implications for clinical practice and public health. Lancet 394:1365–1375. https://doi.org/10.1016/S0140-6736(19)31786-6
doi: 10.1016/S0140-6736(19)31786-6
pubmed: 31609228
Buck HG, Riegel B (2011) The impact of frailty on health related quality of life in heart failure. Eur J Cardiovasc Nurs 10:159–166. https://doi.org/10.1016/j.ejcnurse.2010.06.001
doi: 10.1016/j.ejcnurse.2010.06.001
pubmed: 20587372
Ijaz N, Buta B, Xue QL et al (2022) Interventions for frailty among older adults with cardiovascular disease. J Am Coll Cardiol 79:482–503. https://doi.org/10.1016/j.jacc.2021.11.029
doi: 10.1016/j.jacc.2021.11.029
pubmed: 35115105
pmcid: 8852369
Saxton A, Velanovich V (2011) Preoperative frailty and quality of life as predictors of postoperative complications. Ann Surg 253:1223–1229. https://doi.org/10.1097/SLA.0b013e318214bce7
doi: 10.1097/SLA.0b013e318214bce7
pubmed: 21412145
Rockwood K, Mitnitski A (2007) Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci 62:722–727. https://doi.org/10.1093/gerona/62.7.722
doi: 10.1093/gerona/62.7.722
pubmed: 17634318
Richter D, Guasti L, Walker D et al (2022) Frailty in cardiology: definition, assessment and clinical implications for general cardiology. A consensus document of the Council for Cardiology Practice (CCP), Association for Acute Cardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied Professions (ACNAP), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases (VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO). Eur J Prev Cardiol 29:216–227. https://doi.org/10.1093/eurjpc/zwaa167
doi: 10.1093/eurjpc/zwaa167
pubmed: 34270717
Miani D, Rozbowsky P, Gregori D et al (2003) The Kansas city cardiomyopathy questionnaire: Italian translation and validation. Ital Heart J 4:620–626
pubmed: 14635380
Gillmore JD, Damy T, Fontana M et al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39:2799–2806. https://doi.org/10.1093/eurheartj/ehx589
doi: 10.1093/eurheartj/ehx589
pubmed: 29048471
Fine NM, McMillan JM (2021) Prevalence and prognostic significance of frailty among patients with transthyretin amyloidosis cardiomyopathy. Circ Heart Fail 14:e008105. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008105
doi: 10.1161/CIRCHEARTFAILURE.120.008105
pubmed: 34034508
Fumagalli C, Smorti M, Ponti L et al (2023) Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis. Aging Clin Exp Res 35:1363–1367. https://doi.org/10.1007/s40520-023-02419-6
doi: 10.1007/s40520-023-02419-6
pubmed: 37129709
Broussier A, David JP, Kharoubi M et al (2021) Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg. J Clin Med 10:3415. https://doi.org/10.3390/jcm1015341
doi: 10.3390/jcm1015341
pubmed: 34362197
pmcid: 8348590
Afilalo J, Lauck S, Kim DH et al (2017) Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol 70:689–700. https://doi.org/10.1016/j.jacc.2017.06.024
doi: 10.1016/j.jacc.2017.06.024
pubmed: 28693934
Nakamaru R, Shiraishi Y, Niimi N et al (2023) Phenotyping of elderly patients with heart failure focused on noncardiac conditions: a latent class analysis from a multicenter registry of patients hospitalized with heart failure. J Am Heart Assoc 12:e027689. https://doi.org/10.1161/JAHA.122.027689
doi: 10.1161/JAHA.122.027689
pubmed: 36695300
pmcid: 9973643
Lane T, Fontana M, Martinez-Naharro A et al (2019) Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 140:16–26. https://doi.org/10.1161/CIRCULATIONAHA.118.038169
doi: 10.1161/CIRCULATIONAHA.118.038169
pubmed: 31109193
Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016. https://doi.org/10.1056/NEJMoa1805689
doi: 10.1056/NEJMoa1805689
pubmed: 30145929
Eldhagen P, Lehtonen J, Gude E et al (2023) Health-related quality of life among transthyretin amyloid cardiomyopathy patients. ESC Heart Fail 10:1871–1882. https://doi.org/10.1002/ehf2.14350
doi: 10.1002/ehf2.14350
pubmed: 36946241
pmcid: 10192258
Joseph SM, Novak E, Arnold SV et al (2013) Comparable performance of the Kansas city cardiomyopathy questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail 6:1139–1146. https://doi.org/10.1161/CIRCHEARTFAILURE.113.000359
doi: 10.1161/CIRCHEARTFAILURE.113.000359
pubmed: 24130003
pmcid: 4545244
Grady KL, Andrei AC, Elenbaas C et al (2022) Health-related quality of life in older patients with advanced heart failure: findings from the SUSTAIN-IT study. J Am Heart Assoc 11:e024385. https://doi.org/10.1161/JAHA.121.024385
doi: 10.1161/JAHA.121.024385
pubmed: 35156421
pmcid: 9245796
Wang N, Hales S, Gallagher R et al (2022) Predictors and outcomes of quality of life in elderly patients with heart failure. Am Heart J Plus Cardiol Res Pract 19:100188. https://doi.org/10.1016/j.ahjo.2022.100188
doi: 10.1016/j.ahjo.2022.100188
Johansson I, Joseph P, Balasubramanian K et al (2021) Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation 143:2129–2142. https://doi.org/10.1161/CIRCULATIONAHA.120.050850
doi: 10.1161/CIRCULATIONAHA.120.050850
pubmed: 33906372
Sperry BW, Hanna M, Maurer MS et al (2023) Association of tafamidis with health status in patients with ATTR cardiac amyloidosis. JAMA Cardiol 8:275. https://doi.org/10.1001/jamacardio.2022.5251
doi: 10.1001/jamacardio.2022.5251
pubmed: 36723935
pmcid: 9996391
Denkinger M, Knol W, Cherubini A et al (2023) Inclusion of functional measures and frailty in the development and evaluation of medicines for older adults. Lancet Healthy Longev. https://doi.org/10.1016/S2666-7568(23)00208-8
doi: 10.1016/S2666-7568(23)00208-8
pubmed: 37977177
Fried LP, Tangen CM, Walston J et al (2001) Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 56:M146–M157. https://doi.org/10.1093/gerona/56.3.M146
doi: 10.1093/gerona/56.3.M146
pubmed: 11253156
Kobashigawa J, Shah P, Joseph S et al (2021) Frailty in heart transplantation: report from the heart workgroup of a consensus conference on frailty. Am J Transplant 21:636–644. https://doi.org/10.1111/ajt.16207
doi: 10.1111/ajt.16207
pubmed: 32659872
Studzińska K, Wąż P, Frankiewicz A et al (2022) Employing the multivariate Edmonton scale in the assessment of frailty syndrome in heart failure. J Clin Med 11:4044. https://doi.org/10.3390/jcm11144022
doi: 10.3390/jcm11144022